Division of Pediatric Pulmonology, Department of Pediatrics, CHC MontLégia, Liège, Belgium.
Division of Pediatric Critical Care Medicine, Department of Pediatrics, CHC MontLégia, Liège, Belgium.
Pediatr Pulmonol. 2022 Jan;57(1):245-252. doi: 10.1002/ppul.25699. Epub 2021 Sep 29.
Description of the use of corticosteroids for the management of parapneumonic pleural effusion in children.
Retrospective single-center observational study of all children hospitalized with a diagnosis of parapneumonic pleural effusion during a 15-year period.
We documented 97 cases of parapneumonic effusion during the study period, with a median age (interquartile range [IQR]) of 43 (33-61) months. Most of the children benefited from an evacuation of the pleural effusion (89/97, 91.8%): 21 patients (21.6%) were treated with needle thoracocentesis only, while a chest tube was inserted in 68 children (70.1%). Thirty-two patients (33%) were treated with intrapleural fibrinolysis. Fifty-five children (56.7%) received corticosteroids for persistent fever. The median time (IQR) between hospital admission and initiation of corticosteroids was 5.5 (4-7) days. When corticosteroids were initiated, children had been febrile for 9 (IQR: 8-11) days. The fever ceased in a median (IQR) of 0 (0-1) day after corticosteroids initiation. Only one patient required a video-assisted thoracoscopy that was necessary for morphological reasons (morbid obesity). No children treated with corticosteroids required surgery. All children were discharged from hospital. The median (IQR) hospital length of stay was 11 (8-14) days, with no difference between children with and those without corticosteroids.
Our findings indicate that corticosteroids may be a part of the therapeutic armamentarium for children with parapneumonic effusion when conventional nonsurgical management fails.
描述儿童类肺炎性胸腔积液中糖皮质激素的使用情况。
对 15 年间所有因类肺炎性胸腔积液住院的儿童进行回顾性单中心观察性研究。
研究期间共记录了 97 例类肺炎性胸腔积液病例,中位年龄(四分位距[IQR])为 43(33-61)个月。大多数患儿受益于胸腔积液引流(89/97,91.8%):21 例(21.6%)仅接受了胸腔穿刺术治疗,而 68 例(70.1%)则插入了胸腔引流管。32 例(33%)接受了胸腔内纤维蛋白溶解治疗。55 例(56.7%)因持续性发热接受了糖皮质激素治疗。糖皮质激素治疗开始至入院的中位时间(IQR)为 5.5(4-7)天。开始使用糖皮质激素时,患儿发热时间为 9(IQR:8-11)天。在开始使用糖皮质激素后,中位发热时间为 0(IQR:0-1)天。仅有 1 例患者因形态学原因(病态肥胖)需要进行电视辅助胸腔镜检查。接受糖皮质激素治疗的患儿无一例需要手术。所有患儿均出院。中位(IQR)住院时间为 11(8-14)天,使用和未使用糖皮质激素的患儿之间无差异。
当常规非手术治疗失败时,糖皮质激素可能成为儿童类肺炎性胸腔积液治疗方法的一部分。